New Live In-Person Event
Live satellite symposium preceding the 64th American Society of Hematology (ASH) 2022 Annual Meeting
Registration and Coffee/Tea: 6:30 AM CT
Presentation: 7:00 AM CT
Ernest N. Morial Convention Center
900 Convention Center Blvd.
New Orleans, LA
GREAT HALL A/D
This activity is intended for hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
LLS will present its Friday Satellite Symposium (FSS), Navigating the Frontier of Hematologic Malignancy Therapies, preceding the American Society of Hematology’s (ASH) 64th Annual Meeting on December 9, 2022, in New Orleans, LA. This 3-hour CME accredited symposium, featuring several renowned experts and leaders in blood cancers, will address the most promising therapies and relevant information impacting blood cancer treatment today. Topics will include, bispecific antibodies, new strategies for T cell immunity, targeting intracellular proteins, antibody-drug conjugates and risk protection and individualized therapy. Learners will be able to earn up to 3.0 AMA PRA Category 1 credit(s)™.
Upon completion of this activity, participants will:
- Analyze available data on bispecific antibodies for the treatment of multiple myeloma
- Identify potential T-cell immunotherapeutic strategies for the treatment of lymphomas and other hematologic malignancies
- Describe emerging proteolysis targeting chimeras (PROTACs) under investigation for the treatment of hematologic malignancies
- Assess key data sets and ongoing clinical trials investigating antibody-drug conjugates for the treatment of acute myeloid leukemia (AML)
- Examine the potential utility of circulating tumor DNA for risk prediction and individualizing therapy for diffuse large B-cell lymphoma (DLBCL)
Helen E. Heslop, MD, DSc (Hon) (Chair)
Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Dan L. Duncan Chair
Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Katherine Donovan, PhD
Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Soheil Meshinchi, MD, PhD
Fred Hutchinson Cancer Center
University of Washington
Mark Roschewski, MD
Clinical Director, Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute, NIH
Saad Z. Usmani, MD, MBA, FACP
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, N
Continuing Education Information
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
RMEI Medical Education, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There are no fees for participating in or receiving credit for this CME activity.
This activity is jointly provided by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society.
This educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.